Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review DOI
Emanuele Crupi, Tiago Costa de Pádua, Laura Marandino

et al.

JCO Precision Oncology, Journal Year: 2024, Volume and Issue: 8

Published: Dec. 1, 2024

PURPOSE Aberrant expression of nectin-4 (N4) has been observed in several malignancies emerging as new target for antibody-drug conjugates, especially urothelial carcinoma the bladder (UBC). Limited data on N4 positivity nonurothelial genitourinary (GU) cancers are available. This systematic-review aimed to investigate among GU malignancies. METHODS A systematic literature review was performed March 2023 using PubMed, MEDLINE, and Embase databases according Preferred Reporting Items Systematic Reviews Meta-Analyses statement. Protocol amended incorporate a updated search 2024. RESULTS Twenty-five studies evaluating tumors were included, 14 UBC, three upper tract (UTUC), six histologic subtypes (HS) divergent histology bladder, one papillary renal cell (pRCC), chromophobe RCC (chRCC), two penile cancer, prostate cancer (PCa). Among stratifying per stage higher metastatic (weighted mean [WM], 90.8; range, 59.6-100) non–muscle-invasive (WM, 87.4; 86.7-88.3) than muscle-invasive UC 83.1; 68.2-100). The UBC UTUC 62.9; 44.4-65.7). Immunohistochemistry reported be lower non-UC malignancies, including pRCC 44.1; 44.1-44.1), HS 63.5; 0-100), PCa (WM0; 0-0), chRCC 18.5; 18.5-18.5), 86.5; 61.4-98.3), compared with overall 87.1; 59.6-100). CONCLUSION Non-UC seem have rate UC. appears vary presence HS. predictive prognostic role must further characterized larger prospective studies.

Language: Английский

The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development DOI
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich

et al.

Cancer Discovery, Journal Year: 2024, Volume and Issue: 14(11), P. 2089 - 2108

Published: Oct. 23, 2024

Abstract Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by FDA and more than 210 currently being tested clinical trials. Spanning over 40 years, ADC development has enhanced our understanding multifaceted mechanisms action for this class therapeutics. In article, we discuss key insights into toxicity, efficacy, stability, distribution, fate ADCs. Furthermore, highlight ongoing challenges related to their optimization, rational sequencing strategies, identification predictive biomarkers. Significance: The utilization have allowed relevant improvements prognosis multiple cancer types. Concomitantly, rise oncology produced several challenges, including prediction activity, sequence, minimization side effects, that still too often resemble those cytotoxic molecule they carry. review, retrace years field delve deep these complex therapeutics reasons behind many achievements failures observed date.

Language: Английский

Citations

17
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review DOI
Emanuele Crupi, Tiago Costa de Pádua, Laura Marandino

et al.

JCO Precision Oncology, Journal Year: 2024, Volume and Issue: 8

Published: Dec. 1, 2024

PURPOSE Aberrant expression of nectin-4 (N4) has been observed in several malignancies emerging as new target for antibody-drug conjugates, especially urothelial carcinoma the bladder (UBC). Limited data on N4 positivity nonurothelial genitourinary (GU) cancers are available. This systematic-review aimed to investigate among GU malignancies. METHODS A systematic literature review was performed March 2023 using PubMed, MEDLINE, and Embase databases according Preferred Reporting Items Systematic Reviews Meta-Analyses statement. Protocol amended incorporate a updated search 2024. RESULTS Twenty-five studies evaluating tumors were included, 14 UBC, three upper tract (UTUC), six histologic subtypes (HS) divergent histology bladder, one papillary renal cell (pRCC), chromophobe RCC (chRCC), two penile cancer, prostate cancer (PCa). Among stratifying per stage higher metastatic (weighted mean [WM], 90.8; range, 59.6-100) non–muscle-invasive (WM, 87.4; 86.7-88.3) than muscle-invasive UC 83.1; 68.2-100). The UBC UTUC 62.9; 44.4-65.7). Immunohistochemistry reported be lower non-UC malignancies, including pRCC 44.1; 44.1-44.1), HS 63.5; 0-100), PCa (WM0; 0-0), chRCC 18.5; 18.5-18.5), 86.5; 61.4-98.3), compared with overall 87.1; 59.6-100). CONCLUSION Non-UC seem have rate UC. appears vary presence HS. predictive prognostic role must further characterized larger prospective studies.

Language: Английский

Citations

2